Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity
Authors:
Open Access
- 21 March 2024
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 183, 61-67
Abstract
No abstract availableKeywords
Funding Information
- Novartis Farmacéutica
This publication has 34 references indexed in Scilit:
- Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian CancerJAMA Network Open, 2022
- Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trialAnnals of Oncology, 2022
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancerCancer, 2021
- Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial CancerJAMA Oncology, 2020
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialThe Lancet Oncology, 2019
- Epithelial ovarian cancerThe Lancet, 2019
- Integrated genomic and molecular characterization of cervical cancerNature, 2017
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Integrated genomic analyses of ovarian carcinomaNature, 2011